David R. Helton - Concepedia

Concepedia

Author

David R. Helton

Eli Lilly (United States)

Also Known As

D Helton, D R HELTON, D R Helton, D. R. HELTON, D. R. Helton, D.R. Helton, DAVID R. HELTON, David Helton, David R Helton, David R. Helton

29

Publications

1.3K

Citations

14

H-Index

39

Concepts

All Affiliations

Eli Lilly (United States)Butler University

DR

About

David R. Helton is an author at Eli Lilly (United States) specializing in medicine, neuropharmacology, and pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	9	9	845
2	Social Sciences	3	3	186
3	Natural Sciences	2	2	492
4	Health Sciences	1	1	30
5	Public Health	1	1	82

David R. Helton

×

14

Publications

1.3K

Citations

14

H-Index

	Year	Citations
Design, Synthesis, and Pharmacological Characterization of (+)-2-Aminobicyclo[3.1.0]hexane-2,6-dicarboxylic Acid (LY354740): A Potent, Selective, and Orally Active Group 2 Metabotropic Glutamate Receptor Agonist Possessing Anticonvulsant and Anxiolytic Properties James A. Monn, Matthew J. Valli, Steven M. Massey, Journal of Medicinal Chemistry Pharmacological CharacterizationActive Group 2Psychotropic MedicationPharmacotherapyChemical Biology	1997	392
Anxiolytic and Side-Effect Profile of LY354740: A Potent, Highly Selective, Orally Active Agonist for Group II Metabotropic Glutamate Receptors David R. Helton, J P Tizzano, James A. Monn, Journal of Pharmacology and Experimental Therapeutics	1998	282
LY354740: a metabotropic glutamate receptor agonist which ameliorates symptoms of nicotine withdrawal in rats David R. Helton, Joseph P. Tizzano, James A. Monn, Neuropharmacology Molecular PharmacologyNicotine WithdrawalBehavioral NeuroscienceAddictionNeurophysiology	1997	103
2-Substituted (2<i>SR</i>)-2-Amino-2-((1<i>SR</i>,2<i>SR</i>)-2-carboxycycloprop-1-yl)glycines as Potent and Selective Antagonists of Group II Metabotropic Glutamate Receptors. 2. Effects of Aromatic Substitution, Pharmacological Characterization, and Bioavailability Paul L. Ornstein, Thomas J. Bleisch, M. Brian Arnold, Journal of Medicinal Chemistry Pharmacological CharacterizationSynaptic TransmissionPharmacotherapyChemical BiologyExperimental Pharmacology	1998	100
Nicotine withdrawal: a behavioral assessment using schedule controlled responding, locomotor activity, and sensorimotor reactivity David R. Helton, Deah Modlin, Joseph P. Tizzano, Psychopharmacology Tobacco ControlSubstance AbuseBehavioral SciencesSensorimotor ReactivityNicotine Withdrawal	1993	82
LY303870, a Centrally Active Neurokinin-1 Antagonist with a Long Duration of Action Satish Iyengar, Philip A. Hipskind, Donald R. Gehlert, Journal of Pharmacology and Experimental Therapeutics	1997	58
Intracerebral 1S,3R-1-aminocyclopentane-1,3-dicarboxylic acid (1S,3R-ACPD) produces limbic seizures that are not blocked by ionotropic glutamate receptor antagonists Joseph P. Tizzano, Kelly I. Griffey, J. A. Johnson, Neuroscience Letters Intracerebral 1S,3r-1-aminocyclopentane-1,3-dicarboxylic AcidNeurophysiologyNeuroanatomyLimbic SeizuresMedicine	1993	51
Serotonin-1A antagonists attenuate the effects of nicotine withdrawal on the auditory startle response Kurt Rasmussen, Mary Jeanne Kallman, David R. Helton Synapse	1997	45
The CCK-B antagonist LY288513 blocks effects of diazepam withdrawal on auditory startle Kurt Rasmussen, David R. Helton, James E. Berger, Neuroreport Cck-b Antagonist Ly288513Psychotropic MedicationPsychopharmacologyPharmacotherapyAuditory Startle	1993	32
The proconvulsive activity of quinolone antibiotics in an animal model Patricia D. Williams, David R. Helton Toxicology Letters Quinolone AntibioticsAntibioticsMedicineAntibiotic AdjuvantNeuropharmacology	1991	31

Page 1